EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 9th, 2020 • Verrica Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (this “Agreement”) is entered into as of August 7, 2020 (the “Effective Date”) by and between Lytix Biopharma AS, a company incorporated in Norway, with its principal place of business at Hoffsveien 4, 02775 Oslo, Norway (“Lytix”), and Verrica Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 10 North High Street, Suite 200, West Chester, Pennsylvania 19380 United States (“Verrica”). Lytix and Verrica are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
